Development of fever following first administration of zoledronate as a prognostic factor in advanced non‑small cell lung cancer patients with bone metastases

Izumi,Hiroki; Igishi,Tadashi; Yamasaki,Akira; Takeda,Kennichi; Yanai,Masaaki; Tanaka,Natsumi; Sakamoto,Tomohiro; Nishii‑Ito,Shizuka; Touge,Hirokazu; Kodani,Masahiro; Matsumoto,Shingo; Kawasaki,Yuji; Shimizu,Eiji

doi:10.3892/mco.2017.1447

Development of fever following first administration of zoledronate as a prognostic factor in advanced non‑small cell lung cancer patients with bone metastases

Authors:
- Hiroki Izumi
- Tadashi Igishi
- Akira Yamasaki
- Kennichi Takeda
- Masaaki Yanai
- Natsumi Tanaka
- Tomohiro Sakamoto
- Shizuka Nishii‑Ito
- Hirokazu Touge
- Masahiro Kodani
- Shingo Matsumoto
- Yuji Kawasaki
- Eiji Shimizu
View Affiliations

Affiliations: Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University, Yonago, Tottori 683‑8504, Japan, Department of Respiratory Medicine, Tsuyama First Hospital, Nakashima, Tsuyama 708‑0871, Japan
Published online on: October 10, 2017 https://doi.org/10.3892/mco.2017.1447
Pages: 1000-1004
Copyright: © Izumi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nitrogen‑containing bisphosphonates (N‑BPs), which are usually used for the treatment of advanced cancer with bone metastasis, occasionally cause fever following the first administration. However, it is unclear as to how the development of fever following the first administration of N‑BP is associated with clinical outcome. The aim of the present study was to determine the prognostic value of the development of fever following the first administration of N‑BP in advanced non‑small cell lung cancer patients with bone metastases. The present study reviewed the data of 46 patients with advanced non‑small cell lung cancer who were administered zoledronate (ZOL), an N‑BP, for bone metastasis, between March 2009 and March 2011 in the Department of Medical Respirology at Tottori University Hospital. Clinicopathological factors were evaluated using univariate and multivariate analyses, and these factors were compared between the fever and non‑fever groups. Of the 46 patients, 15 (32.6%) developed fever following the first administration of ZOL. No significant differences were observed in the clinicopathological characteristics between the two groups. The overall survival in the fever group was significantly longer compared with the non‑fever group (median survival time: 33.4 vs. 15.7 months, P=0.04), and the development of fever following the first ZOL administration was independently associated with longer overall survival. The development of fever following the first ZOL administration was an independent prognostic factor in advanced non‑small cell lung cancer patients with bone metastases. Thus, ZOL‑associated fever may be a predictive factor for an undefined, survival‑promoting effect of ZOL.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Coleman RE: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
3	Dong M, Feng FY, Zhang Y, Xie GR, Wang YJ, Liu JW, Song ST, Zhou QH, Ren J, Jiao SC, et al: Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma. Zhonghua Zhong Liu Za Zhi. 30:215–220. 2008.(In Chinese). PubMed/NCBI
4	Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 21:3150–3157. 2003. View Article : Google Scholar : PubMed/NCBI
5	Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony H and Wilhelm M: Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 96:384–392. 2000.PubMed/NCBI
6	Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, et al: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12:631–641. 2011. View Article : Google Scholar : PubMed/NCBI
7	Avilés A, Nambo MJ, Neri N, Castañeda C, Cleto S and Huerta-Guzmán J: Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 24:227–230. 2007. View Article : Google Scholar : PubMed/NCBI
8	Kunzmann V, Bauer E and Wilhelm M: Gamma/delta T-cell stimulation by pamidronate. N Engl J Med. 340:737–738. 1999. View Article : Google Scholar : PubMed/NCBI
9	Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R and Tonini G: Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res. 23:649–654. 2003. View Article : Google Scholar : PubMed/NCBI
10	Bonneville M and Scotet E: Human Vgamma9Vdelta2 T cells: Promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol. 18:539–546. 2006. View Article : Google Scholar : PubMed/NCBI
11	Reid IR, Gamble GD, Mesenbrink P, Lakatos P and Black DM: Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 95:4380–4387. 2010. View Article : Google Scholar : PubMed/NCBI
12	Nakamura H, Ando K, Shinmyo T, Morita K, Mochizuki A, Kurimoto N and Tatsunami S: Female gender is an independent prognostic factor in non-small-cell lung cancer: A meta-analysis. Ann Thorac Cardiovasc Surg. 17:469–480. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kris MG, Johnson BE, Berry LD, et al: NIH Public Access. Select Target Drugs. 311:1998–2006. 2014.
14	Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 23:2513–2520. 2005. View Article : Google Scholar : PubMed/NCBI
15	Triebel F and Hercend T: Subpopulations of human peripheral T gamma delta lymphocytes. Immunol Today. 10:186–188. 1989. View Article : Google Scholar : PubMed/NCBI
16	Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, Sato K, Hosoi A, Nakajima J, Yoshida Y, et al: Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy. 10:842–856. 2008. View Article : Google Scholar : PubMed/NCBI
17	Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H and Kakimi K: Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: A phase I clinical study. J Immunother. 34:202–211. 2011. View Article : Google Scholar : PubMed/NCBI
18	Kobayashi H, Tanaka Y, Yagi J, Minato N and Tanabe K: Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother. 60:1075–1084. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kobayashi H and Tanaka Y: γδ T cell immunotherapy-A review. Pharmaceuticals (Basel). 8:40–61. 2015. View Article : Google Scholar : PubMed/NCBI